These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31562657)

  • 1. BAFF inhibition in SLE-Is tolerance restored?
    Jackson SW; Davidson A
    Immunol Rev; 2019 Nov; 292(1):102-119. PubMed ID: 31562657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAFF and selection of autoreactive B cells.
    Liu Z; Davidson A
    Trends Immunol; 2011 Aug; 32(8):388-94. PubMed ID: 21752714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
    Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
    Martin J; Cheng Q; Laurent SA; Thaler FS; Beenken AE; Meinl E; Krönke G; Hiepe F; Alexander T
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell activating factor targeted therapy and lupus.
    Boneparth A; Davidson A
    Arthritis Res Ther; 2012; 14 Suppl 4(Suppl 4):S2. PubMed ID: 23281926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus.
    Huang W; Moisini I; Bethunaickan R; Sahu R; Akerman M; Eilat D; Lesser M; Davidson A
    J Immunol; 2011 Dec; 187(12):6571-80. PubMed ID: 22102726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
    Kowalczyk-Quintas C; Chevalley D; Willen L; Jandus C; Vigolo M; Schneider P
    Front Immunol; 2018; 9():2698. PubMed ID: 30524439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BAFF/APRIL system in SLE pathogenesis.
    Vincent FB; Morand EF; Schneider P; Mackay F
    Nat Rev Rheumatol; 2014 Jun; 10(6):365-73. PubMed ID: 24614588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cracking the BAFF code.
    Mackay F; Schneider P
    Nat Rev Immunol; 2009 Jul; 9(7):491-502. PubMed ID: 19521398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells.
    Du SW; Jacobs HM; Arkatkar T; Rawlings DJ; Jackson SW
    J Immunol; 2018 Dec; 201(11):3258-3268. PubMed ID: 30373855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.